Tonix Pharmaceuticals has signed a research collaboration and exclusive licensing agreement with the University of Alberta in Canada for three new vaccine candidates to prevent Covid-19. The partnership will develop the three vaccine candidates, which are based on the horsepox…
US clinical trial sites are most affected due to the Covid-19 pandemic
With over 1,000 trials being disrupted and more trials being added to this category daily, there is a direct impact on trial site activation and patient enrollment. With the recent development of the current Covid-19 pandemic, there has been an…
Ferring’s gut microbiome drug clears phase 3 trial in C. diff
Ferring Pharma has reported what it says is the first positive phase 3 trial of a microbiome therapy – based on healthy bacteria – showing it can reduce recurrences of a serious gastrointestinal infection. The ongoing trial is testing the…
Moderna Moves into Phase II Testing of COVID-19 Vaccine Candidate
Shares of Moderna jumped nearly 11% from the moment the bell rung this morning following its announcement that it received regulatory permission to begin a Phase II study of its mRNA vaccine candidate for COVID-19. In a brief announcement this…
FDA Gives Novartis Approval for First-Ever Therapy for NSCLC Tumors with METex14
The first treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) who also have a specific genetic mutation was approved Wednesday by the U.S. Food and Drug Administration (FDA). Developed by Novartis, the drug, Tabrecta™ (capmatinib), is designed…
Pfizer/BioNTech dose first US patients with COVID-19 vaccine
Pfizer and its development partner BioNTech have begun dosing the first people in the US with a potential COVID-19 vaccine, as part of their ongoing phase 1/2 clinical trial. The companies said that the first participants were dosed at the NYU Grossman School of…
FDA Approves AstraZeneca’s Farxiga for Heart Failure in Adults with Reduced Ejection Fraction
The U.S. Food and Drug Administration (FDA) announced on Tuesday that it has approved dapagliflozin, also known under the brand name Farxiga, for the treatment of heart failure in adults with reduced ejection fraction. The drug can potentially reduce the…
Alexion Set to Acquire Portola Pharmaceuticals in $1.41 Billion Deal
Shares of Portola Pharmaceuticals more than doubled in premarket trading on news that Boston-based Alexion Pharmaceuticals is acquiring the company and its blood-disorder assets for $1.41 billion in cash. Alexion said the acquisition of Portola will bolster its commercial portfolio…
Hepatitis drug could be tested against COVID-19 in India
India’s Zydus Cadila wants to test a form of interferon, usually used against hepatitis B and C, as a potential treatment for the virus that causes COVID-19. According to press reports the company has asked the regulator, the Drugs Controller General…
BerGenBio raises 45 million euros for COVID-19 drug development
Norway’s BerGenBio has raised 500 million Norwegian kroner – around $45.4 million euros – in an oversubscribed private placement to develop its pipeline that includes a potential COVID-19 therapy. As reported by pharmaphorum last week, BerGenBio’s bemcentinib is the first drug to be tested in a UK…
